SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.
There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.
Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.
Company Details
- Founded
- 2009
- Address
- Melbourne, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://synkinase.com
- HQ
- Melbourne
Synkinase Questions
Synkinase's website is http://synkinase.com
Synkinase's LinkedIn profile is https://cn.linkedin.com/company/synkinase-pty-ltd
Synkinase's industry is
Biotechnology Research
Synkinase's top competitors are
United States Biological Inc,
Corey Pharmaceuticals,
Revmab Biosciences Usa, Inc.,
Qingdao Qianshan Science And Technology Innovation Co., Ltd,
Chimerigen Laboratories, Llc,
South African Chemical Institute,
Neweast Biosciences,
South Bay Bio,
武汉健民大鹏药业有限公司,
Viwit Pharmaceuticals.
Synkinase's categories are Biotechnology Research
Synkinase's founding year is 2009
